We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 18, 2021

Role of CD19 and Specific KIT-D816 on Risk Stratification Refinement in t(8;21) AML Induced With Different Cytarabine Intensities

Cancer Medicine

 

Additional Info

Cancer Medicine
Role of CD19 and Specific KIT-D816 on Risk Stratification Refinement in t(8;21) Acute Myeloid Leukemia Induced With Different Cytarabine Intensities
Cancer Med 2020 Dec 31;[EPub Ahead of Print], B Wang, B Yang, Y Ling, J Zhang, X Hua, W Gu, F Yan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading